成交额突出个股方面，阿里巴巴成交226.05亿港元，上涨2.32%，云栖大会月底召开提振预期；腾讯控股成交105.36亿港元，股价持平；泡泡玛特成交 89.12亿港元，下跌6.43%。 恒生行业指数方面，非必需性消费行业指数上涨1.00%，能源业指数上涨0.83%，必需性消费行业指数上涨0.57%。跌幅方面，原材料业指数下跌1.08%， 综合企业指数下跌0.88%。 【导读】药捷安康狂飙近116%，近4个交易日累计涨近500%！带动18A板块大涨 9月15日，香港三大股指全线收涨，恒生指数涨0.22%，报26446.56点；恒生科技指数涨0.91%，报6043.61点；恒生中国企业指数涨0.21%，报9384.76点。 大市成交2901.95亿港元。南向资金净买入144.73亿港元。 泡泡玛特遭摩根大通下调评级至"中性"，股价逆市跌6.43%，收报259.00港元/股。 恒生指数成份股中33只上涨，52只下跌。药明生物涨6.47%，市场看好其创新药管线进展；理想汽车涨4.56%；农夫山泉涨4.11%，领涨蓝筹。 | 序号 | 名称 | 代码 | 现价 | 涨跌 | 涨跌幅 ▼ | 成交额 | 年初至今 | | ...

Core Viewpoint - The article highlights the significant surge in the stock price of the biotech company,药捷安康, which increased by nearly 116% in a single day, contributing to a substantial rise in the 18A sector of unprofitable biotech companies in Hong Kong [12][18]. Group 1: Stock Performance - 药捷安康's stock opened and surged to a high of 124.10%, closing at 415.00 HKD per share, marking a 115.58% increase [12][24]. - Over four trading days, 药捷安康's stock price has cumulatively risen by nearly 500% [18]. - The overall 18A sector, which includes unprofitable biotech companies, saw an increase of 15.63%, leading all concept sectors [20]. Group 2: Market Reactions - Following 药捷安康's announcement regarding its clinical trial for its core product, the stock price of several other companies in the 18A sector also rose significantly, with notable increases such as 脑动极光 up 34.93% and MIRXES up 25.91% [23]. - The article mentions that the Hong Kong stock market saw a general uptick, with the Hang Seng Index rising by 0.22% and the Hang Seng Tech Index increasing by 0.91% [2][4]. Group 3: Industry Developments - The article notes that the automotive sector, particularly the new energy vehicle industry, is also experiencing a positive trend, with companies like 宁德时代 and 理想汽车 seeing significant stock price increases [26][32]. - The Chinese government has introduced measures to stabilize the automotive industry, which includes a commitment from 17 major vehicle manufacturers to ensure supplier payment terms do not exceed 60 days [32].

Group 1 - As of June 20, 2025, there have been 32 new listings in the Hong Kong stock market, raising a total net amount of HKD 77.969 billion, significantly higher than the total of HKD 13.464 billion raised in the first half of 2024 [1] - The number of A-share companies listing in Hong Kong has increased, with 6 A+H share companies successfully listing this year, reflecting strong demand from investors for quality A-share listings [1] - The 6 A+H share companies had a strong debut in the Hong Kong market, with most experiencing double-digit percentage increases, and Chifeng Jilong Gold Mining Co. seeing a cumulative increase of 117.20% [1] Group 2 - The A-share company Sanhua Intelligent Controls is set to list in Hong Kong on June 23, 2025, with an issue price of HKD 22.53, aiming to raise HKD 0.811 billion for product development and global expansion [2] Group 3 - Traditional consumer stocks have underperformed, while new consumption stocks have thrived, with companies like Haitian Flavoring and Food Co. and Shubao International seeing significant stock price increases [3] - New consumption stocks such as milk tea brands have shown remarkable performance, with shares of Misha Group and Hu Shang Ayi increasing by 153.83% and 20.67% respectively since their listings [3] Group 4 - The trend of collectible toy stocks has also emerged, with Pop Mart International seeing a cumulative stock price increase of over 100% [4] - The toy company Blok has attracted significant interest, with its Hong Kong public offering being oversubscribed by 6,000 times [4] Group 5 - Five unprofitable biotech companies have listed in Hong Kong this year, with Mirxes and Brainstorm Aurora showing strong stock performance since their listings, with increases of 48.71% and 113.66% respectively [5][6] - The focus on "hard tech + medical" sectors has led to high valuations for these unprofitable biotech firms, despite their current losses [6] Group 6 - At least 10 more companies are expected to list in the remaining days of June, including traditional consumer stocks and unprofitable biotech firms, with their performance yet to be determined [7][8]